| 徐绮腻,王鸿彪.激素受体阳性晚期乳腺癌的内分泌治疗进展[J].中国肿瘤,2017,26(10):808-811. |
| 激素受体阳性晚期乳腺癌的内分泌治疗进展 |
| Advances of Endocrine Therapy in Hormone Receptor-positive Metastatic Breast Cancer |
| 投稿时间：2016-11-18 |
| DOI：10.11735/j.issn.1004-0242.2017.10.A012 |
|
 |
| 中文关键词: 乳腺肿瘤 内分泌治疗 靶向药物 |
| 英文关键词:breast neoplasms endocrine therapy targeted drug |
| 基金项目: |
|
| 摘要点击次数: 1786 |
| 全文下载次数: 517 |
| 中文摘要: |
| 摘 要：内分泌耐药是激素受体阳性晚期乳腺癌的治疗难题之一。根据耐药机制，内分泌治疗引入靶向药物有望逆转或延迟耐药，并已在临床研究中取得验证。寻找分子标志物，选择获益人群，是这个领域发展的重要方向。 |
| 英文摘要: |
| Abstract：Resistance to endocrine therapy is one of the major obstacles in hormone receptor-positive metastatic breast cancer. With understanding of mechanisms in resistance，introduction of targeted drugs into endocrine therapy may reverse or delay drug resistance，which has been proven effective in clinical trials. Identification of biomarkers to select patients with benefit is the direction for future research. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|